Preloader

Japan approves AstraZeneca’s Forxiga to treat chronic kidney disease in patients with and without type-2 diabetes, Health News, ET HealthWorld

United Kingdom : AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without…

CXCL12/CXCR4 axis as a key mediator in atrial fibrillation via bioinformatics analysis and functional identification

1. Giuseppe L, Fabian SG, Gianfranco C. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217–221. Google Scholar  2. Staerk L, Sherer JA,…